Merck & Company Inc (MRK)vsPhaos Technology Holdings (Cayman) Limited (POAS)
MRK
Merck & Company Inc
$120.79
+1.41%
HEALTHCARE · Cap: $283.78B
POAS
Phaos Technology Holdings (Cayman) Limited
$0.35
+9.35%
HEALTHCARE · Cap: $5.29M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 34218423% more annual revenue ($65.77B vs $192,200). MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
POAS
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-40.6%
Fair Value
$80.96
Current Price
$120.79
$39.83 premium
Intrinsic value data unavailable for POAS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Revenue surging 38.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : POAS
The strongest argument for POAS centers on Revenue Growth, Debt/Equity. Revenue growth of 38.8% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : POAS
The primary concerns for POAS are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while POAS is a hypergrowth play — different risk/reward profiles.
POAS is growing revenue faster at 38.8% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (50/100 vs 23/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Phaos Technology Holdings (Cayman) Limited
HEALTHCARE · MEDICAL DEVICES · USA
Phaos Technology Holdings (Cayman) Limited, through its subsidiary, Phaos Technology Pte. The company is headquartered in Singapore.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?